儿童和青年中采用成分和剂量明确的CD19 CAR-T细胞实现意向性治疗的 leukemia 缓解
Intent-to-treat leukemia remission by CD19 CAR T cells of defined formulation and dose in children and young adults
这项研究要解决的是：早期CD19 CAR-T细胞产品成分不明确、疗效不稳定、毒性难以预测的问题。研究者制备了一种CD4/CD8成分明确、CAR表达均一、效应细胞分化有限的CD19 CAR-T产品，并在45例复发或难治性B系急性淋巴细胞白血病儿童和青年中开展1期试验。结果显示，93%的患者获得了符合全部质量标准的产品；最大耐受剂量为每公斤体重10^6个CAR-T细胞，未出现产品毒性导致的死亡或脑水肿；意向治疗微小残留病阴性缓解率为89%，接受氟达拉滨和环磷酰胺清淋的患者中达100%；23%出现可逆的严重细胞因子释放综合征和/或可逆的严重神经毒性。这意味着，标准化生产CD19 CAR-T细胞可获得高效且毒性可耐受的治疗效果，为这类预后很差的患者提供了可行方案。
为什么推荐给您：成分明确的CD19 CAR-T产品在儿童白血病中取得高缓解率，属早期人体阳性关键结果。
不需要生物学背景，多打比方
正在获取全文并生成讲解（拿不到全文就依据摘要），大约需要 30–60 秒…
已等待 0 秒
这篇还没有动画
动画会把研究的流程、作用机制和关键结果一步一步演示出来，每一步都标明出自原文哪里。制作大约需要 30–60 秒。
摘要Abstract
Transitioning CD19-directed chimeric antigen receptor (CAR) T cells from early-phase trials in relapsed patients to a viable therapeutic approach with predictable efficacy and low toxicity for broad application among patients with high unmet need is currently complicated by product heterogeneity resulting from transduction of undefined T-cell mixtures, variability of transgene expression, and terminal differentiation of cells at the end of culture. A phase 1 trial of 45 children and young adults with relapsed or refractory B-lineage acute lymphoblastic leukemia was conducted using a CD19 CAR product of defined CD4/CD8 composition, uniform CAR expression, and limited effector differentiation. Products meeting all defined specifications occurred in 93% of enrolled patients. The maximum tolerated dose was 10^6 CAR T cells per kg, and there were no deaths or instances of cerebral edema attributable to product toxicity. The overall intent-to-treat minimal residual disease-negative (MRD-) remission rate for this phase 1 study was 89%. The MRD- remission rate was 93% in patients who received a CAR T-cell product and 100% in the subset of patients who received fludarabine and cyclophosphamide lymphodepletion. Twenty-three percent of patients developed reversible severe cytokine release syndrome and/or reversible severe neurotoxicity. These data demonstrate that manufacturing a defined-composition CD19 CAR T cell identifies an optimal cell dose with highly potent antitumor activity and a tolerable adverse effect profile in a cohort of patients with an otherwise poor prognosis. This trial was registered at www.clinicaltrials.gov as #NCT02028455.